Cargando…
ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer
The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoid acid receptor-related orphan receptor γ (ROR-γ) is overexpressed and amplified in...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030109/ https://www.ncbi.nlm.nih.gov/pubmed/27019329 http://dx.doi.org/10.1038/nm.4070 |
_version_ | 1782454627620356096 |
---|---|
author | Wang, Junjian Zou, June X. Xue, Xiaoqian Cai, Demin Zhang, Yan Duan, Zhijian Xiang, Qiuping Yang, Joy C. Louie, Maggie C. Borowsky, Alexander D. Gao, Allen C. Evans, Christopher P. Lam, Kit S. Xu, Jianzhen Kung, Hsing-Jien Evans, Ronald M. Xu, Yong Chen, Hong-Wu |
author_facet | Wang, Junjian Zou, June X. Xue, Xiaoqian Cai, Demin Zhang, Yan Duan, Zhijian Xiang, Qiuping Yang, Joy C. Louie, Maggie C. Borowsky, Alexander D. Gao, Allen C. Evans, Christopher P. Lam, Kit S. Xu, Jianzhen Kung, Hsing-Jien Evans, Ronald M. Xu, Yong Chen, Hong-Wu |
author_sort | Wang, Junjian |
collection | PubMed |
description | The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoid acid receptor-related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors. ROR-γ recruits coactivators SRC-1 and -3 to an AR-RORE to stimulate AR gene transcription. ROR-γ antagonists suppress the expression of AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR gene network. Lastly, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing but not AR-negative xenograft PCa models, and effectively sensitized CRPC tumors to enzalutamide, without overt toxicity in mice. Together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and a potential therapeutic target for advanced PCa. |
format | Online Article Text |
id | pubmed-5030109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
record_format | MEDLINE/PubMed |
spelling | pubmed-50301092016-09-28 ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer Wang, Junjian Zou, June X. Xue, Xiaoqian Cai, Demin Zhang, Yan Duan, Zhijian Xiang, Qiuping Yang, Joy C. Louie, Maggie C. Borowsky, Alexander D. Gao, Allen C. Evans, Christopher P. Lam, Kit S. Xu, Jianzhen Kung, Hsing-Jien Evans, Ronald M. Xu, Yong Chen, Hong-Wu Nat Med Article The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoid acid receptor-related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors. ROR-γ recruits coactivators SRC-1 and -3 to an AR-RORE to stimulate AR gene transcription. ROR-γ antagonists suppress the expression of AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR gene network. Lastly, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing but not AR-negative xenograft PCa models, and effectively sensitized CRPC tumors to enzalutamide, without overt toxicity in mice. Together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and a potential therapeutic target for advanced PCa. 2016-03-28 2016-05 /pmc/articles/PMC5030109/ /pubmed/27019329 http://dx.doi.org/10.1038/nm.4070 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Wang, Junjian Zou, June X. Xue, Xiaoqian Cai, Demin Zhang, Yan Duan, Zhijian Xiang, Qiuping Yang, Joy C. Louie, Maggie C. Borowsky, Alexander D. Gao, Allen C. Evans, Christopher P. Lam, Kit S. Xu, Jianzhen Kung, Hsing-Jien Evans, Ronald M. Xu, Yong Chen, Hong-Wu ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer |
title | ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer |
title_full | ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer |
title_fullStr | ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer |
title_full_unstemmed | ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer |
title_short | ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer |
title_sort | ror-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030109/ https://www.ncbi.nlm.nih.gov/pubmed/27019329 http://dx.doi.org/10.1038/nm.4070 |
work_keys_str_mv | AT wangjunjian rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT zoujunex rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT xuexiaoqian rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT caidemin rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT zhangyan rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT duanzhijian rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT xiangqiuping rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT yangjoyc rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT louiemaggiec rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT borowskyalexanderd rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT gaoallenc rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT evanschristopherp rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT lamkits rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT xujianzhen rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT kunghsingjien rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT evansronaldm rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT xuyong rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer AT chenhongwu rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer |